Receptor tyrosine kinase Axl is required for resistance of leukemic cells to FLT3-targeted therapy in acute myeloid leukemia-Reference-Cited by-同舟云学术

Receptor tyrosine kinase Axl is required for resistance of leukemic cells to FLT3-targeted therapy in acute myeloid leukemia

Published:2015-06-19 Issue:12 Volume:29 Page:2382-2389
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Park I-K,Mundy-Bosse B,Whitman S P,Zhang X,Warner S L,Bearss D J,Blum W,Marcucci G,Caligiuri M A

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu2015147.pdf

Reference43 articles.

1. Brown P, Small D . FLT3 inhibitors: a paradigm for the development of targeted therapeutics for paediatric cancer. Eur J Cancer 2004; 40: 707–721, discussion; 722–724.

2. Knapper S . FLT3 inhibition in acute myeloid leukaemia. Br J Haematol 2007; 138: 687–699.

3. Stirewalt DL, Radich JP . The role of FLT3 in haematopoietic malignancies. Nat Rev Cancer 2003; 3: 650–665.

4. Gilliland DG, Griffin JD . The roles of FLT3 in hematopoiesis and leukemia. Blood 2002; 100: 1532–1542.

5. Whitman SP, Archer KJ, Feng L, Baldus C, Becknell B, Carlson BD et al. Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study. Cancer Res 2001; 61: 7233–7239.

Cited by 131 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Understanding mechanisms of resistance to FLT3 inhibitors in adult FLT3-mutated acute myeloid leukemia to guide treatment strategy;Critical Reviews in Oncology/Hematology;2024-09

2. Concomitant targeting of FLT3 and SPHK1 exerts synergistic cytotoxicity in FLT3-ITD+ acute myeloid leukemia by inhibiting β-catenin activity via the PP2A-GSK3β axis;Cell Communication and Signaling;2024-08-07

3. Adaptive resistance to FLT3 inhibitors is potentiated by ROS-driven DNA repair signalling;2024-07-26

4. Ningetinib, a novel FLT3 inhibitor, overcomes secondary drug resistance in acute myeloid leukemia;Cell Communication and Signaling;2024-07-08

5. Mechanisms of Resistance to Targeted Therapies in AML;Annual Review of Cancer Biology;2024-06-12